{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:57:36Z","timestamp":1794855456609,"version":"4.9.1"},"reference-count":27,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2008,8,15]],"date-time":"2008-08-15T00:00:00Z","timestamp":1218758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the efficacy, tolerability, and treatment satisfaction after initiating treatment with sildenafil 50\u2003mg and later titrating to 100\u2003mg, compared with continuing treatment with sildenafil 50\u2003mg, in men with erectile dysfunction (ED).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>A multicentre, parallel\u2010group trial was conducted in two 4\u2010week periods. In period 1, patients received 50\u2010mg doses of sildenafil single\u2010blinded for 4\u2003weeks. In period 2, patients were randomized to double\u2010blind, placebo\u2010controlled treatment with sildenafil 50\u2003mg or sildenafil 100\u2003mg for 4\u2003weeks. All patients were aged \u226518\u2003years with a documented clinical diagnosis of ED (score of \u226425 on the International Index of Erectile Function, IIEF, Erectile Function, EF, domain), and met the prescribing criteria for sildenafil 50\u2003mg and 100\u2003mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Of 492 enrolled patients (mean age 53\u2003years,\n                      <jats:sc>sd<\/jats:sc>\n                      11), 476 (97%) completed period 1 and 473 (96%) completed period 2. Patients receiving sildenafil 50\u2003mg in period 1 had an increase in the mean (\n                      <jats:sc>sd<\/jats:sc>\n                      ) baseline EF domain score from 12.8\u2003(5.2) to 22.5\u2003(6.6) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001), and improved scores on the Quality of Erection Questionnaire (QEQ) and Sexual Experience Questionnaire (SEX\u2010Q). The IIEF EF domain scores were similar in the two groups at baseline and randomization. Patients titrated to the 100\u2010mg dose (237 men) showed a significantly greater improvement than those who continued on the 50\u2010mg dose (240;\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001). There was a significant increase in QEQ and SEX\u2010Q scores in patients titrated to sildenafil 100\u2003mg compared with patients continuing at sildenafil 50\u2003mg. At either sildenafil dose, headache, flushing and hot flushes were the most common adverse events. Neither the frequency nor the severity of adverse events increased with titration to sildenafil 100\u2003mg.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>After initial treatment with sildenafil 50\u2003mg, patients titrated to 100\u2003mg showed further increases in efficacy and satisfaction with no increase in the number or severity of adverse events than in those remaining on the starting dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2008.07908.x","type":"journal-article","created":{"date-parts":[[2008,8,15]],"date-time":"2008-08-15T07:49:17Z","timestamp":1218786557000},"page":"1645-1650","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy, tolerability and satisfaction with sildenafil citrate 100\u2010mg titration compared with continued 50\u2010mg dose treatment in men with erectile dysfunction"],"prefix":"10.1111","volume":"102","author":[{"given":"Jacques","family":"Buvat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Hatzichristou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Mart\u00ednez\u2010Jabaloyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Schnetzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,21]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901250"},{"key":"e_1_2_8_3_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"NIH Consensus Development Panel on Impotence","volume":"270","author":"NIH Consensus Conference. Impotence.","year":"1993","journal-title":"JAMA"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90292-5"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01606-0"},{"key":"e_1_2_8_6_2","first-page":"47","article-title":"Sildenafil: an orally active type 5 cyclic GMP\u2010specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction","volume":"8","author":"Boolell M","year":"1996","journal-title":"Int J Impot Res"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805143382001"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00586-X"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.178.4.325"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901047"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01688-6"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.12.005"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565120-00003"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.07.020"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.05.041"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00441.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900895"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.04.040"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901498"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00238-0"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2006.00422.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00694.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00582-2"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.1998.00050.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.06.027"},{"key":"e_1_2_8_26_2","first-page":"8","article-title":"A 36\u2010week, open label, non\u2010comparative study to assess the long\u2010term safety of sildenafil citrate (VIAGRA) in patients with erectile dysfunction","volume":"102","author":"Goldstein I","year":"1999","journal-title":"Int J Clin Pract Suppl"},{"key":"e_1_2_8_27_2","first-page":"36","article-title":"Appropriate starting dose of VIAGRA\u00ae (sildenafil citrate) for the treatment of erectile dysfunction: pooled analysis of flexible\u2010dose, placebo\u2010controlled, double\u2010blind studies and open\u2010label extension","volume":"2","author":"Levinson IP","year":"2005","journal-title":"J Sex Med"},{"key":"e_1_2_8_28_2","first-page":"480","article-title":"Long\u2010term efficacy and safety of sildenafil for patients with erectile dysfunction","volume":"66","author":"Sheu JY","year":"2003","journal-title":"J Chin Med Assoc"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2008.07908.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2008.07908.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:39:38Z","timestamp":1761737978000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2008.07908.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,21]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1464-410X.2008.07908.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2008.07908.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,21]]},"assertion":[{"value":"2008-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}